Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Edwards Lifesciences (GB:0REN)
LSE:0REN
RESEARCH TOOLSreports
Holding GB:0REN?
Track your performance easily
0REN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Edwards Lifesciences News
Bulls Say, Bears Say
Bulls Say
Clinical Trials And ApprovalsPotential TAVR approval in asymptomatic patients could lead to significant volume growth for Edwards Lifesciences Corp.
Financial Strength And Strategic InvestmentsEdwards Lifesciences is a great business with an exceptional balance sheet, approaching $4 billion in cash, and positive clinical data expected from upcoming events.
Sales And Market ExpectationsEdwards Lifesciences Corp.'s U.S. TAVR sales are expected to be above consensus projections.
Bears Say
Financial PerformanceManagement made comments that both margins and earnings will be substantially lower in 2025 vs 2024, with growth expected to resume in 2026.
Growth OutlookThe company's stock is priced for TAVR growth of about 5-6%, which aligns with its current market penetration, suggesting limited upside potential.
Market ShareSurvey respondents expect market share erosion for Edwards Lifesciences Corp. in the U.S. TAVR market.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.91% Insiders
22.39% Mutual Funds
0.93% Other Institutional Investors
53.13% Public Companies and
Individual Investors
0REN FAQ
What was Edwards Lifesciences’s price range in the past 12 months?
Currently, no data Available
What is Edwards Lifesciences’s market cap?
Currently, no data Available
When is Edwards Lifesciences’s upcoming earnings report date?
Edwards Lifesciences’s upcoming earnings report date is Oct 24, 2024 which is in 5 days.
How were Edwards Lifesciences’s earnings last quarter?
Edwards Lifesciences released its earnings results on Jul 24, 2024. The company reported CHF0.6 earnings per share for the quarter, beating the consensus estimate of CHF0.595 by CHF0.005.
Is Edwards Lifesciences overvalued?
According to Wall Street analysts Edwards Lifesciences’s price is currently Undervalued.
Does Edwards Lifesciences pay dividends?
Edwards Lifesciences does not currently pay dividends.
What is Edwards Lifesciences’s EPS estimate?
Edwards Lifesciences’s EPS estimate is CHF0.57.
How many shares outstanding does Edwards Lifesciences have?
Edwards Lifesciences has 602,400,000 shares outstanding.
What happened to Edwards Lifesciences’s price movement after its last earnings report?
Edwards Lifesciences reported an EPS of CHF0.6 in its last earnings report, beating expectations of CHF0.595. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Edwards Lifesciences?
Among the largest hedge funds holding Edwards Lifesciences’s share is Fisher Asset Management LLC. It holds Edwards Lifesciences’s shares valued at 764M.
---
Edwards Lifesciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF65.81 (― Upside)
CHF65.81 (― Upside)
Blogger Sentiment
Bullish
GB:0REN Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $87.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
0.80%
12-Months-Change
Fundamentals
Return on Equity
21.35%
Trailing 12-Months
Asset Growth
12.16%
Trailing 12-Months
Company Description
Edwards Lifesciences
Incorporated in 1958, California-based Edwards Lifesciences Corp. is a medical technology company, which specializes in structural heart disease and critical care and surgical monitoring. It reports in three segments: Transcatheter Aortic Valve Replacements, Transcatheter Mitral and Tricuspid Therapies and Surgical Structural Heart and Critical Care.
---
0REN Earnings Call
Q2 2024
0:00 / 0:00
---
0REN Net sales Breakdown
64.61% Transcatheter Aortic Valve Replacement
16.64% Surgical Structural Heart
15.46% Critical Care
3.29% Transcatheter Mitral and Tricuspid Therapies
---
0REN Stock 12 Month Forecast
Average Price Target
―Edwards Lifesciences
―
Boston Scientific
―
Medtronic
―
Integra Lifesciences
―
Stryker
―
Best Analysts Covering 0REN
1 Year
1 Year Success Rate
24/34 ratings generated profit
1 Year Average Return
+14.13%
reiterated a buy rating last month
Copying Suraj Kalia's trades and holding each position for 1 Year would result in 70.59% of your transactions generating a profit, with an average return of +14.13% per trade.
---